Natural history of chronic HBV infection: Special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 1, 2011, Pages S8-

  Villa, Erica ^a   Fattovich, Giovanna ^b   Mauro, Antonella ^a   Pasino, Michela ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Chronic hepatitis; Hepatitis B virus; Inactive carrier state; Prognosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER HISTOLOGY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; VIRUS CARRIER; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 78650667897     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60686-X     Document Type: Article

References (38)

1. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
2. Hadziyannis SJ Unraveling the natural course of the so-called " inactive HBsAg or HBV carrier state" Hepatol Int 2007, 1:281-284.
3. De Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993, 118:191-194.
4. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994, 106:1000-1005.
5. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004, 127:756-763.
6. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867.
7. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
8. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-834.
9. Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007, 22:383-388.
10. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999, 94:2246-2250.
11. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52.
12. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-89.
13. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
14. Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134:1376-1384.
15. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005, 77:173-179.
16. Chu CM, Liaw YF HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
17. Fong TL, Di Bisceglie A, Gerber MA, et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993, 18:1313-1318.
18. Kuhns M, Mason A, McNamara A, et al. Polymerase chain reaction in the detection of HBV DNA after HBsAg clearance in chronic hepatitis B. Gastroenterology 1992, 103:1649-1656.
19. Loriot MA, Marcellin P, Bismuth E, et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-Hbe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992, 15:32-36.
20. Hoofnagle JH, Seeff LB, Bales ZB, et al. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978, 298:1379-1383.
21. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008, 135:1192-1199.
22. Chu CM, Lin DY, Liaw YF Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes (Lond) 2007, 31:871-875.
23. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002, 36:543-546.
24. Chu CM, Liaw YF Spontaneous relapse of hepatitis in inactive carriers. Hep Intl 2007, 1:311-318.
25. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
26. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
27. Velasco M, González-Cerón M, de la Fuente C, et al. Clinical and pathological study of asymptomatic HBsAg carriers in Chile. Gut 1978, 19:569-571.
28. Chon CY, Han KH, Lee KS, et al. Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers with normal liver function tests and no hepatomegaly. Yonsei Med J 1996, 37:295-301.
29. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006, 119:e9-e16. 71.
30. Fattovich G, Bortolotti F, Donato F Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 482:335-352.
31. Crook PD, Jones ME, Hall AJ Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003, 32:118-124.
32. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145:1039-1047.
33. Iloeje UH, Yang HI, Jen CL, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
34. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005, 42:188-194.
35. Tong MJ, Nguyen MO, Tong LT, et al. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2009, 7:889-893.
36. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51:1531-1537.
37. Chen YC, Chu CM, Liaw YF Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010, 51:435-444.
38. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896-900.